Lucid Group Company
Lucid aims to develop a unique 3-in-1diagnostic device. The device will help intuitive, fast and economic measure biophysiological markers (pressure, sensation and muscle contractility – via EMG), enabling a more precise diagnosis of the functional deficits in faecal incontinence at primary care. The company helps other organisations innovate, developing and delivering brand-aware products and services for health care, wellbeing, security, pharma, and hazardous environments. Lucid designs devices collaboratively with users, illustrating alternative solutions and using clickable prototypes to observe every interaction before detailed programming. The company validates that products work in inclusive, practical ways and make sense to users early. Lucid develops wearable and invasive medical sensors, contactless charging, wireless control and communications systems.
Industry:
P4 medicine
Headquarters:
Manchester, United Kingdom
Founded Date:
2002
Employees Number:
11-50
Funding Status:
Private
Investors Number:
4
Total Funding:
£719 947
Estimated Revenue:
< £780 000
Last Funding Date:
02-01-2015
Last Funding Type:
Grant
Register and Claim Ownership